Korro Bio, Inc. Research and Development Expense
Korro Bio, Inc. (KRRO) reported Research and Development Expense of $13.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Korro Bio, Inc. research and development expense for the quarter ending 2026-06-30 was $13.59M, a 32.52% decline year-over-year.
- Korro Bio, Inc. research and development expense for the quarter ending 2026-03-31 was $12.95M, a 34.39% decline year-over-year.
- Korro Bio, Inc. research and development expense for the quarter ending 2025-12-31 was $10.98M, a 35.24% decline year-over-year.
- Korro Bio, Inc. research and development expense for the quarter ending 2025-09-30 was $13.82M, a 13.43% decline year-over-year.
- Korro Bio, Inc. research and development expense for fiscal 2025 was $65.58M, a 3.05% increase from fiscal 2024.
- Korro Bio, Inc. research and development expense for fiscal 2024 was $63.64M, a 11.15% increase from fiscal 2023.
- Korro Bio, Inc. research and development expense for fiscal 2023 was $57.25M, a 35.66% increase from fiscal 2022.
- Korro Bio, Inc. research and development expense for fiscal 2022 was $42.20M, a 30.73% decline from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $13.59M 10-Q · filed 2026-08-06 | $26.54M 10-Q · filed 2026-08-06 | $37.52M derived: sum of 3 quarters · filed 2026-08-06 | $51.34M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $12.95M 10-Q · filed 2026-05-07 | $23.94M derived: sum of 2 quarters · filed 2026-05-07 | $37.76M derived: sum of 3 quarters · filed 2026-05-07 | $57.89M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $10.98M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $24.80M derived: sum of 2 quarters · filed 2026-03-12 | $44.94M derived: sum of 3 quarters · filed 2026-08-06 | $65.58M 10-K · filed 2026-03-12 | ||||
| 2025-09-30 | $13.82M 10-Q · filed 2025-11-12 | $33.95M derived: sum of 2 quarters · filed 2026-08-06 | $54.59M 10-Q · filed 2025-11-12 | $70.66M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $20.14M 10-Q · filed 2026-08-06 | $21.03M 10-Q · filed 2025-08-12 | $39.87M 10-Q · filed 2026-08-06 | $40.77M 10-Q · filed 2025-08-12 | $56.84M derived: sum of 3 quarters · filed 2026-08-06 | $72.80M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $19.74M 10-Q · filed 2026-05-07 | $36.70M derived: sum of 2 quarters · filed 2026-05-07 | $52.66M derived: sum of 3 quarters · filed 2026-05-07 | $69.80M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $16.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $32.93M derived: sum of 2 quarters · filed 2026-03-12 | $50.06M derived: sum of 3 quarters · filed 2026-03-12 | $63.64M 10-K · filed 2026-03-12 | ||||
| 2024-09-30 | $15.96M 10-Q · filed 2025-11-12 | $33.10M derived: sum of 2 quarters · filed 2025-11-12 | $46.67M 10-Q · filed 2025-11-12 | $62.10M derived: sum of 4 quarters · filed 2025-11-12 | ||||
| 2024-06-30 | $17.14M 10-Q · filed 2025-08-12 | $30.71M 10-Q · filed 2025-08-12 | $46.13M derived: sum of 3 quarters · filed 2025-08-12 | $60.14M derived: sum of 4 quarters · filed 2025-08-12 | ||||
| 2024-03-31 | $13.57M 10-Q · filed 2025-05-07 | $28.99M derived: sum of 2 quarters · filed 2025-05-07 | $43.00M derived: sum of 3 quarters · filed 2025-05-07 | $56.13M derived: sum of 4 quarters · filed 2025-05-07 | ||||
| 2023-12-31 | $15.42M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $29.43M derived: sum of 2 quarters · filed 2025-03-18 | $42.56M derived: sum of 3 quarters · filed 2025-03-18 | $57.25M 10-K · filed 2025-03-18 | ||||
| 2023-09-30 | $14.01M 10-Q · filed 2024-11-12 | $2.56M 10-Q · filed 2023-11-02 | $27.14M derived: sum of 2 quarters · filed 2024-11-12 | $41.83M 10-Q · filed 2024-11-12 | $18.51M 10-Q · filed 2023-11-02 | $45.26M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $13.13M 10-Q · filed 2024-08-13 | $4.59M 10-Q · filed 2023-08-10 | $27.82M 10-Q · filed 2024-08-13 | $15.95M 10-Q · filed 2023-08-10 | $31.25M derived: sum of 3 quarters · filed 2024-08-13 | $42.97M derived: sum of 4 quarters · filed 2024-08-13 | ||
| 2023-03-31 | $14.69M 10-Q · filed 2024-05-14 | $11.36M 10-Q · filed 2023-05-12 | $18.13M derived: sum of 2 quarters · filed 2024-05-14 | $29.84M derived: sum of 3 quarters · filed 2024-05-14 | $43.11M derived: sum of 4 quarters · filed 2024-05-14 | |||
| 2022-12-31 | $3.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | $15.15M derived: sum of 2 quarters · filed 2024-03-26 | $28.42M derived: sum of 3 quarters · filed 2024-03-26 | $42.20M 10-K · filed 2024-03-26 | $49.42M 10-K · filed 2023-03-10 | |||
| 2022-09-30 | $11.71M 10-Q · filed 2023-11-02 | $24.99M derived: sum of 2 quarters · filed 2023-11-02 | $38.77M 10-Q · filed 2023-11-02 | $51.52M derived: sum of 4 quarters · filed 2023-11-02 | ||||
| 2022-06-30 | $13.27M 10-Q · filed 2023-08-10 | $27.05M 10-Q · filed 2023-08-10 | $39.81M derived: sum of 3 quarters · filed 2023-08-10 | $55.47M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | $13.78M 10-Q · filed 2023-05-12 | $26.54M derived: sum of 2 quarters · filed 2023-05-12 | $42.20M derived: sum of 3 quarters · filed 2023-05-12 | $59.60M derived: sum of 4 quarters · filed 2023-05-12 | ||||
| 2021-12-31 | $12.75M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $28.42M derived: sum of 2 quarters · filed 2023-03-10 | $45.82M derived: sum of 3 quarters · filed 2023-03-10 | $60.92M 10-K · filed 2023-03-10 | ||||
| 2021-09-30 | $15.66M 10-Q · filed 2022-11-08 | $33.06M derived: sum of 2 quarters · filed 2022-11-08 | $48.17M 10-Q · filed 2022-11-08 | $60.00M derived: sum of 4 quarters · filed 2022-11-08 | ||||
| 2021-06-30 | $17.40M 10-Q · filed 2022-08-09 | $32.51M 10-Q · filed 2022-08-09 | $44.34M derived: sum of 3 quarters · filed 2022-08-09 | $54.49M derived: sum of 4 quarters · filed 2022-08-09 | ||||
| 2021-03-31 | $15.11M 10-Q · filed 2022-05-04 | $26.93M derived: sum of 2 quarters · filed 2022-05-04 | $37.09M derived: sum of 3 quarters · filed 2022-05-04 | $45.85M derived: sum of 4 quarters · filed 2022-05-04 | ||||
| 2020-12-31 | $11.83M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $21.98M derived: sum of 2 quarters · filed 2022-03-15 | $30.75M derived: sum of 3 quarters · filed 2022-03-15 | $37.41M 10-K · filed 2022-03-15 | ||||
| 2020-09-30 | $10.15M 10-Q · filed 2021-11-15 | $18.92M derived: sum of 2 quarters · filed 2021-11-15 | $25.59M 10-Q · filed 2021-11-15 | $31.78M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-06-30 | $8.76M 10-Q · filed 2021-08-12 | $15.43M 10-Q · filed 2021-08-12 | $21.63M derived: sum of 3 quarters · filed 2021-08-12 | $26.85M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | $6.67M 10-Q · filed 2021-05-13 | $12.87M derived: sum of 2 quarters · filed 2021-05-13 | $18.09M derived: sum of 3 quarters · filed 2021-05-13 | $22.01M derived: sum of 4 quarters · filed 2021-05-13 | ||||
| 2019-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-29 | $11.42M derived: sum of 2 quarters · filed 2021-03-29 | $15.34M derived: sum of 3 quarters · filed 2021-03-29 | $18.78M 10-K · filed 2021-03-29 | ||||
| 2019-09-30 | $5.22M 10-Q · filed 2020-11-16 | $9.14M derived: sum of 2 quarters · filed 2020-11-16 | $12.59M 10-Q · filed 2020-11-16 | $15.51M derived: sum of 4 quarters · filed 2020-11-16 | ||||
| 2019-06-30 | $3.92M 10-Q · filed 2020-08-12 | $7.37M 10-Q · filed 2020-08-12 | $10.29M derived: sum of 3 quarters · filed 2020-08-12 | $13.84M derived: sum of 4 quarters · filed 2020-08-12 | ||||
| 2019-03-31 | $3.45M 10-Q · filed 2020-05-14 | $6.37M derived: sum of 2 quarters · filed 2020-05-14 | $9.92M derived: sum of 3 quarters · filed 2020-05-14 | |||||
| 2018-12-31 | $2.92M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $6.47M derived: sum of 2 quarters · filed 2020-03-26 | $11.88M 10-K · filed 2020-03-26 | |||||
| 2018-09-30 | $3.55M 10-Q · filed 2019-11-18 | $8.96M 10-Q · filed 2019-11-18 | ||||||
| 2017-12-31 | $11.97M 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B | |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Curanex Pharmaceuticals Inc (CURX) | United States | $0.138B | |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| TuHURA Biosciences, Inc./NV (HURA) | United States | $0.134B | -4.88 |
| Unicycive Therapeutics, Inc. (UNCY) | United States | $0.134B | -3.70 |
| NRX Pharmaceuticals, Inc. (NRXP) | United States | $0.131B | -6.31 |
| MEDICINOVA INC (MNOV) | United States | $0.130B | -6.04 |
| IMMUNIC, INC. (IMUX) | United States | $0.127B | -1.88 |